The disease is characterized by progressive motor, cognitive, and psychiatric decline. Three treatments are approved to treat ...

Swiss drugmaker Novartis will pay up to $2.9 billion for PTC Therapeutics' promising experimental drug for a neurological ...

Research indicates β-blockers may reduce the risk of motor diagnosis and slow symptom progression in Huntington's disease, ...

A patient in the UK has received a new therapy for Huntington’s disease, which experts hope could slow progression of the ...

A common heart drug may slow the progression of Huntington's disease (HD), according to a new study by University of Iowa ...

New therapy for Huntington’s disease ‘may slow progression’ - There are thought to be around 7,000 people living with ...

PTC Therapeutics surges 21% after entering exclusive global collaboration with Novartis for Huntington's disease program ...

The Wicked Witch of the West and I have something in common: We both use our fatal flaws to our advantage—for her, her green ...

Novartis is paying $1 billion upfront for global rights to PTC Therapeutics’ midphase Huntington's disease program, helping ...

Novartis is paying $1 billion upfront in a licensing deal for an experimental Huntington’s disease treatment from PTC ...

Novartis will partner with PTC Therapeutics to develop PTC’s PTC518 Huntington's disease program and an unspecified number of related molecules, through an up-to-$2.9 billion exclusive global license ...